Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
暂无分享,去创建一个
G. Hortobagyi | R. Theriault | H. Wheeler | D. Blayney | J. Simeone | G. Hortobagyi | A. Lipton | R. Knight | L. Porter | D. Reitsma | M. Heffernan | J. Seaman | A. Lipton | R. Theriault | K. Mellars | I. Kennedy | C. Sinoff | S. Allan | Douglas W. Blayney | Robert K. Knight | Allan Lipton | John J. Seaman
[1] A. Dobson,et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. , 1981, Journal of chronic diseases.
[2] P. Woll,et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). , 1988, British Journal of Cancer.
[3] D. Tong,et al. The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group , 1982, Cancer.
[4] I. Henderson,et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Perey,et al. Treatment of tumor-induced osteolysis by APD. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[6] A. Zwinderman,et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. , 1991, European journal of cancer.
[7] R. Rubens,et al. Bone metastases and breast cancer. , 1985, Cancer treatment reviews.
[8] A. Paradiso,et al. Intravenous Administration of Cyclophosphamide, Methotrexate and 5-Fluorouracil in Metastatic Breast Cancer. A Pilot Study , 1988, Tumori.
[9] A. Lipton,et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose‐seeking study , 1994, Cancer.
[10] R. Coleman,et al. Osteoclast inhibition for the treatment of bone metastases. , 1993, Cancer treatment reviews.
[11] C. Spurr,et al. Vincristine, doxorubicin, and cyclophosphamide versus low‐dose intravenous cyclophosphamide, methotrexate, and 5‐fluorouracil in advanced breast cancer. A randomized trial of the piedmont oncology association , 1982, Cancer.
[12] Max H. Myers,et al. Manual for Staging of Cancer , 1992 .
[13] R. Rubens,et al. Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland , 1977, European journal of cancer.
[14] Smith Cw. Smith-McGuckin spot. , 1985 .
[15] A. Howell,et al. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. , 1988, BMJ.
[16] F. Costa,et al. Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study. , 1988, European journal of cancer & clinical oncology.
[17] J. Hermans,et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Parvinen,et al. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone. , 1985, Acta radiologica. Oncology.
[19] A. Johnston. Pathology of Metastatic Tumors in Bone , 1970, Clinical orthopaedics and related research.
[20] H. Fleisch. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[21] G. Bjelkengren,et al. A phase II study of combined 5‐fluorouracil and mitomycin C in advanced breast cancer , 1982, Cancer.
[22] L. Crinò,et al. Vindesine and mitomycin c in chemotherapy refractory advanced breast cancer , 1986, Cancer.
[23] M. Kovacs,et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.